


(Maintain)	<b>Buy</b>
Target price	<b>▲ W170,000</b>
Current price (10/24/24)	W131,000
Upside	29.8%

OP (24F, Wbn)	-7
Consensus OP (24F, Wbn)	-9
EPS growth (24F, %)	TTB
Market EPS growth (24F, %)	76.2
P/E (24F, x)	354.1
Market P/E (24F, x)	10.4
KOSDAQ	734.59

Market cap (Wbn)	4,790
Shares (mn)	37
Free float (%)	69.9
Foreign ownership (%)	10.4
Beta (12M)	1.72
52-week low (W)	35,500
52-week high (W)	131,000

(%)	1M	6M	12M
Absolute	27.6	92.1	265.4
Relative	33.2	125.5	290.4



Mirae Asset Securities Co., Ltd.

Mihwa Seo

mihwa.seo@miraeasset.com

# LigaChem Biosciences

## Setbacks at competitors creating opportunities

### Raise TP to W170,000; maintain Buy rating

We maintain our Buy rating on LigaChem Biosciences (LigaChem) and lift our target price to W170,000 (from W86,000). Our target price is based on the sum of the values of six pipeline drugs; our significant upward revision reflects: 1) a higher valuation of the existing pipeline (from W2.6tr to W3.9tr); and 2) the addition of three new pipeline drugs (LCB97, LCB02A, and LNCB74; W1.8tr). Notably, we see potential for additional large-scale licensing deals for the company's preclinical candidates, following the recently disclosed agreement with Ono Pharmaceutical (worth up to W1tr).

### Investment points

1) LigaChem is no longer merely a platform company. Although it lacks commercialized products, the company has secured licensing agreements with major global pharmaceutical firms (including Ono Pharmaceutical, Johnson & Johnson, and Amgen), thus establishing a strong track record and differentiating itself from other antibody-drug conjugate (ADC) developers. If LCB14 (HER2-targeting ADC) receives conditional approval in China, we expect the company to garner a valuation on par with that of ImmunoGen (acquired for US\$10.1bn).

2) Competitors' previous failures in ADC development have created opportunities for LigaChem. In particular, the repeated failures of competing Trop2 ADC candidates in clinical trials have raised expectations for LigaChem's Trop2 ADC. As such, we now see an increased likelihood that Janssen will exercise its options on the candidate (likely in 2025), which could bring in a milestone payment of US\$220mn.

3) Big pharma companies are eager to acquire more ADC candidates, but the number of available candidates has decreased. This presents another opportunity for LigaChem, especially given that many ADC players have been acquired by big pharma companies, leaving few independent ADC-focused companies in the market. LigaChem is the second-largest listed ADC company by market cap, behind only Daiichi Sankyo. All in all, the continued demand for ADC candidates combined with the shrinking supply of available assets makes LigaChem well-positioned for future deal opportunities, especially given its proven technology and track record.

(Dec.)	2022	2023	2024F	2025F	2026F
Revenue (Wbn)	33	34	123	312	280
OP (Wbn)	-50	-81	-7	187	151
OP margin (%)	-151.5	-238.2	-5.7	59.9	53.9
NP (Wbn)	-45	-74	13	164	163
EPS (W)	-1,650	-2,634	370	4,482	4,463
ROE (%)	-20.5	-40.1	3.3	22.8	18.5
P/E (x)	-	-	354.1	29.2	29.4
P/B (x)	5.4	12.1	7.5	5.9	4.9
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0

Notes: Under non-consolidated K-IFRS; NP is attributable to owners of the parent

Source: Company data, Mirae Asset Securities Research estimates

**Table 1. LigandChem: Licensing agreements**

(Wbn)

Platform	Date	Partner	Pipeline	Value	
ADC	Candidate	8/15	Fosun Pharma	LCB14 (HER2-MMAF)	20.8
		5/20	Iksuda	LCB73 (CD19-pPBD)	278.4
		10/20	CStone	LCB71 (ROR1-pPBD)	409.9
		12/20	Pyxis	LCB67 (DLK1-MMAE)	325.5
		12/21	Iksuda	LCB14 (HER2-MMAF)	1,186
		12/23	Janssen	LCB84 (Trop2-MMAE)	2,246
	Platform	10/24	Ono Pharmaceutical	LCB97 (L1CAM-ADC)	9,434
		3/19	Takeda	ADC platform (linkers for three targets)	454.8
		6/21	Iksuda	ADC platform (linker/toxin for six targets)	920
		11/21	Sotio	ADC platform (five targets)	1,213
	12/22	Amgen	ADC platform (five targets)	1,605	
	10/24	Ono Pharmaceutical	ADC platform (undisclosed)	Undisclosed	
Synthetic drugs	6/09	Green Cross/Lee's Pharma	Nokxaban	Undisclosed	
	12/16	Haihe Biopharma	Delpazolid	24	
	5/17	Bridge Biotherapeutics	BBT-877	30	

Source: Company data, Mirae Asset Securities Research

**Table 2. LigandChem: TP calculation**

(Wbn)

	Value	Notes
Value of pipeline drugs	5,654	
LCB14 (HER2-MMAF)	1,328	817 previously
LCB84 (Trop2-MMAE)	1,789	1,649 previously
LCB71 (ROR1-pPBD)	759	90 previously
LCB97 (L1CAM-ADC)	820	New
LCB02A (Claudin18.2 ADC)	284	New
LNCB74 (B7-H4 ADC)	675	New
Net borrowings	(580)	
Fair value	6,235	
No. of shares ('000)	36,428	
Fair value/share	171,147	
Target price	170,000	

Source: Mirae Asset Securities Research

**Table 3. Value of LCB14 (HER2 ADC)**

(US\$mn)

		2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size	Enhertu	3,426	4,813	6,738	8,943	10,483	12,146	14,018	14,719	15,455	16,228	17,039	17,891
Growth			40%	40%	33%	17%	16%	15%	5%	5%	5%	5%	5%
M/S				1%	1%	2%	5%	10%	15%	20%	20%	20%	20%
Clinical status				China launch			FDA approval						
Est. sales				34	89	210	607	1,402	2,208	3,091	3,246	3,408	3,578
Royalties (10% est.)				3	9	21	61	140	221	309	325	341	358
FCF				3	7	17	49	112	177	247	260	273	286
NPV				2	6	13	35	76	110	142	138	134	130
Terminal value			2,578										
PV of terminal value			1,172										
Sum of PVs			1,960										
Risk-adjusted NPV			980										

Source: Mirae Asset Securities Research

**Table 4. Value of LCB84 (Trop2 ADC)**

(US\$mn)

	2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size (lung cancer + TNBC)	61,923	70,547	79,234	87,725	96,155	102,973	111,028	119,479	128,443	138,106	148,525	159,761
Lung cancer	31,630	35,843	38,922	41,902	46,314	50,384	54,794	59,837	65,222	71,092	77,491	84,465
TNBC	30,293	34,704	40,312	45,823	49,841	52,589	56,234	59,642	63,221	67,014	71,035	75,297
Growth		14%	12%	11%	10%	7%	8%	8%	8%	8%	8%	8%
M/S								2%	3%	3%	3%	3%
Clinical status		Phase 1 start	Phase 1 end	Phase 2 start	Phase 2 end	Phase 3 start	Phase 3 end	FDA approval				
Est. sales								2,390	3,211	4,143	4,456	4,793
Royalties (15% est.)								358	321	414	446	479
Milestones		80	220		200		300	623				
FCF		64	176		160		240	785	257	331	356	383
NPV		64	163		126		162	489	148	176	175	174
Terminal value		3,453										
PV of terminal value		2,570										
Sum of PVs		4,248										
Risk-adjusted NPV		1,274										

Source: Mirae Asset Securities Research

**Table 5. Value of LCB71 (ROR1 ADC)**

(US\$mn)

	2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size (Hodgkin's/non-Hodgkin's lymphoma)	15,444	15,538	17,239	18,799	21,431	24,405	28,014	31,852	36,630	42,124	48,443	55,709
Hodgkin's lymphoma	1,405	1,403	1,491	1,549	1,575	1,595	1,595	1,630	1,875	2,156	2,479	2,851
Non-Hodgkin's lymphoma	14,039	14,135	15,748	17,250	19,856	22,810	26,419	30,222	34,755	39,969	45,964	52,858
Growth		1%	11%	9%	14%	14%	15%	14%	15%	15%	15%	15%
M/S								2%	3%	3%	3%	5%
Clinical status		Phase 2 start		Phase 2 end		Phase 3 end		FDA approval				
Est. sales								637	916	1,264	1,453	2,785
Royalties (15% est.)								96	137	190	218	418
Milestones				150		204						
FCF				120		163		76	110	152	174	334
NPV				103				48	63	81	86	152
Terminal value		3,011										
PV of terminal value		1,369										
Sum of PVs		1,901										
Risk-adjusted NPV		570										

Source: Mirae Asset Securities Research

**Table 6. Value of LCB97 (L1CAM ADC)**

(US\$mn)

	2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size (lung cancer/TNBC)	61,923	70,547	79,234	87,725	96,155	102,973	111,028	119,479	128,443	138,106	148,525	159,761
Lung cancer	31,630	35,843	38,922	41,902	46,314	50,384	54,794	59,837	65,222	71,092	77,491	84,465
TNBC	30,293	34,704	40,312	45,823	49,841	52,589	56,234	59,642	63,221	67,014	71,035	75,297
Growth		14%	12%	11%	10%	7%	8%	10%	10%	10%	10%	10%
M/S									1%	2%	3%	3%
Clinical status			Phase 1 start	Phase 1 end	Phase 2 start	Phase 2 end	Phase 3 start	Phase 3 end	FDA approval			
Est. sales									642	2,072	4,456	4,793
Royalties (15% est.)									96	311	668	719
Milestones				100		150		200				
FCF				80		120		160	77	249	535	575
NPV				68				100	44	132	263	262
Terminal value		5,180										
PV of terminal value		5,180										
Sum of PVs		6,049										
Risk-adjusted NPV		605										

Source: Mirae Asset Securities Research

**Table 7. Value of LCB02A (Claudin18.2 ADC)**

(US\$mn)

	2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size (stomach/pancreatic cancer)	1,786	2,043	2,385	2,891	3,459	4,670	5,870	7,290	8,303	9,458	10,774	12,275
Stomach cancer	1,468	1,661	1,904	2,296	2,659	3,075	3,539	4,012	4,534	5,123	5,789	6,541
Pancreatic cancer	318	382	481	595	800	1,595	2,331	3,278	3,770	4,335	4,985	5,733
Growth		14%	17%	21%	20%	35%	26%	24%	14%	14%	14%	14%
M/S									1%	2%	3%	3%
Clinical status			Phase 1 start	Phase 1 end	Phase 2 start	Phase 2 end	Phase 3 start	Phase 3 end	FDA approval			
Est. sales									42	142	323	368
FCF									33	113	259	295
NPV									19	60	127	134
Terminal value		2,653										
PV of terminal value		2,653										
Sum of PVs		2,994										
Risk-adjusted NPV		210										

Source: Mirae Asset Securities Research

**Table 8. Value of LNCB74 (B7-H4 ADC)**

(US\$mn)

	2023	2024F	2025F	2026F	2027F	2028F	2029F	2030F	2031F	2032F	2033F	2034F
Market size (breast/ovarian/uterine cancer)	34,098	39,388	46,508	52,748	57,466	60,867	65,104	69,323	73,613	78,172	83,016	88,163
Breast cancer	30,293	34,704	40,312	45,823	49,841	52,589	56,234	59,642	63,221	67,014	71,035	75,297
Ovarian cancer	3,096	3,444	4,646	5,173	5,790	6,341	6,862	7,582	8,189	8,844	9,551	10,315
Uterine cancer	709	1,240	1,550	1,752	1,835	1,937	2,008	2,099	2,204	2,314	2,430	2,551
Growth		16%	18%	13%	9%	6%	7%	6%	6%	6%	6%	6%
M/S									1%	2%	3%	3%
Clinical status			Phase 1 start	Phase 1 end	Phase 2 start	Phase 2 end	Phase 3 start	Phase 3 end	FDA approval			
Est. sales									368	1,173	2,490	2,645
FCF									294.5	938.1	1,992.4	2,115.9
NPV									170	499	980	962
Terminal value		19,057										
PV of terminal value		7,347										
Sum of PVs		9,959										
Risk-adjusted NPV		498										

Source: Mirae Asset Securities Research


**Table 9. Peer valuation table: ADC players**

Company	ADC Therapeutics	Daiichi Sankyo	Pyxis Oncology	Mersana Therapeutics	LigaChem	
Ticker	ADCT US	4568 JP	PYXS US	MRSN US	141080 KS	
Market cap (US\$m)	311	64,033	196	259	4,406	
2023	Revenue (US\$m, Wbn)	70	11,093	-	37	34
	OP (US\$m, Wbn)	-166	1,465	-82	-180	-81
	EBITDA (US\$m, Wbn)	-165	1,879	-78	-174	-76
	NP (US\$m, Wbn)	-240	1,390	-74	-172	-74
	EPS (US\$, W)	-3	1	-2	-1	-2,595
	P/E (x)	-	46	-	-	-
	P/B (x)	-	5	1	8	12
	ROE (%)	-	13	-52	-266	-40
	EV/EBITDA (x)	-	30	-	-	-
	P/S (x)	2	6	-	7	54
2024F	Revenue (US\$m, Wbn)	73	12,162	16	25	130
	OP (US\$m, Wbn)	-128	1,684	-70	-91	-11
	EBITDA (US\$m, Wbn)	-114	2,102	-	-95	-6
	NP (US\$m, Wbn)	-159	1,421	-63	-88	6
	EPS (US\$, W)	-2	1	-1	-1	287
	P/E (x)	-	44	-	-	420
	P/B (x)	-	6	-	-	7
	ROE (%)	81	13	-	-1,072	1
	EV/EBITDA (x)	-	28	-	-	-
	P/S (x)	4	5	12	10	34
2025F	Revenue (US\$m, Wbn)	84	14,044	-	33	204
	OP (US\$m, Wbn)	-135	2,144	-96	-98	49
	EBITDA (US\$m, Wbn)	-96	2,611	-	-95	54
	NP (US\$m, Wbn)	-160	1,753	-91	-96	58
	EPS (US\$, W)	-1	1	-1	-1	1,279
	P/E (x)	-	35	-	-	94
	P/B (x)	-	5	-	-	6
	ROE (%)	62	15	-	-124	8
	EV/EBITDA (x)	-	23	-	-	72
	P/S (x)	4	5	-	8	22

Note: As of Oct 17, 2024


Source: Bloomberg, Mirae Asset Securities Research

**Figure 1. Trop2-targeted therapy overview**




Source: *Pharmacology & Therapeutics*(2022), Mirae Asset Securities Research

**Figure 2. LCB84 (Trop2-MMAE): NSCLC treatment efficacy (1)**



Source: Company materials, Mirae Asset Securities Research

**Figure 3. LCB84 (Trop2-MMAE): NSCLC treatment efficacy (2)**




Source: Company materials, Mirae Asset Securities Research

**Table 10. Trop2 ADC clinical failures**

Company	Time	Candidate	Clinical phase	Indication	Details
Gilead/ Immunomedics	Jan. 2024	Trodelvy	Phase 3	NSCLC	Failure to improve OS; failure to demonstrate statistical significance, although the Trodelvy group displayed longer survival than the chemotherapy group
	May 2024		Phase 3	Metastatic urothelial cancer	Failure to achieve OS; adverse effects related to neutropenia complications
AstraZeneca/ Daiichi Sankyo	Sep. 2024	Dato-DXd	Phase 3	HER2-low/HER2-negative breast cancer	Failure to improve OS
	Sep. 2024		Phase 3	NSCLC	Failure to improve OS; demonstrate to achieve statistical significance


Source: Company data, Mirae Asset Securities Research

**Figure 4. Dato-DXd: Clinical results for NSCLC (TROPION-Lung01): PFS improved by 0.7 months**




Source: Daiichi Sankyo, Mirae Asset Securities Research

**Figure 5. Dato-DXd: Clinical results for non-squamous NSCLC (TROPION-Lung01): PFS improved by 1.9 months**




Source: Daiichi Sankyo, Mirae Asset Securities Research

**Figure 6. Interim results from phase 1 study of LCB71 (ROR1 ADC): Low adverse effects**




Source: CStone, Mirae Asset Securities Research

**Figure 7. Key characteristics of ADCs under clinical development**




Source: *Nature Reviews Drug Discovery*(2024), Mirae Asset Securities Research

Figure 8. LigaChem: Key pipeline candidates



Source: Company materials, Mirae Asset Securities Research

Figure 9. Next drivers: New targets and new payloads




Source: Company materials, Mirae Asset Securities Research

**Table 11. LigaChem: New pipeline candidates**

	Target	Payload	Details	Projected milestones
Antibody	LCB02A	CLDN18.2	Topoisomerase inhibitor	Potential best-in-class treatment for gastric cancer; utilizes LigaChem's proprietary platform
	LCB97	L1CAM	MMAE	Novel target for solid tumors
	LCB36	CD20xCD22	dPBD	LigaChem's first bispecific antibody ADC
	LCB22A	Unique antigen	MMAE	Targets cancer-specific glycosylation
	LCB45A	Unique antigen	MMAE	Targets cancer-specific glycosylation
Payload	LCB37		Novel topoisomerase inhibitor	Payload is a novel topoisomerase inhibitor
	LCB39		STING-agonist	Payload is an immune modulator
				GLP toxicity study to be completed in 2H24; IND filing in US expected in 1H26

Source: Company data, Mirae Asset Securities Research

**Figure 10. Causes of toxicity in ADC therapies**



Source: *Cancers* (2023), Mirae Asset Securities Research

**Figure 11. High-dose administration feasible with reduced side effects using the same payload**

Target	Adcetris, Padcev, Tivdak, Polivy	LCB A	LCB B
Payload	VC-MMAE	MMAE	MMAE
DAR	4; stochastic	4	4
Lethal dose		15 mg/kg (single)	>10 mg/kg (Q3Wx2)
Tolerated Dose		12 mg/kg (Q3Wx2)	10 mg/kg
NOAEL/HNSTD	3 mg/kg (Q3Wx2)	12 mg/kg (Q3Wx2)	10 mg/kg
Notes	Seagen's HNSTD for MMAE = 3 mg/kg		

Source: Company materials, Mirae Asset Securities Research

LigaChem Biosciences (141080 KQ)

**Income statement (summarized)**

(Wbn)	2023	2024F	2025F	2026F
<b>Revenue</b>	<b>34</b>	<b>123</b>	<b>312</b>	<b>280</b>
<b>Cost of revenue</b>	<b>16</b>	<b>16</b>	<b>17</b>	<b>17</b>
<b>GP</b>	<b>18</b>	<b>107</b>	<b>295</b>	<b>263</b>
<b>SG&amp;A expenses</b>	<b>99</b>	<b>114</b>	<b>109</b>	<b>112</b>
<b>OP (adj.)</b>	<b>-81</b>	<b>-7</b>	<b>187</b>	<b>151</b>
<b>OP</b>	<b>-81</b>	<b>-7</b>	<b>187</b>	<b>151</b>
<b>Non-operating profit</b>	<b>5</b>	<b>21</b>	<b>25</b>	<b>31</b>
Net financial income	5	18	25	31
Net income from associates	1	1	0	0
Pretax profit	-76	14	212	182
Income tax	-2	1	48	19
Profit from continuing operations	-74	13	164	163
Profit from discontinued operations	0	0	0	0
<b>NP</b>	<b>-74</b>	<b>13</b>	<b>164</b>	<b>163</b>
Attributable to owners	-74	13	164	163
Attributable to minority interests	0	0	0	0
<b>Total comprehensive income</b>	<b>-74</b>	<b>12</b>	<b>164</b>	<b>163</b>
Attributable to owners	-74	12	164	163
Attributable to minority interests	0	0	0	0
EBITDA	-76	-2	191	154
FCF	-64	41	161	162
EBITDA margin (%)	-223.5	-1.6	61.2	55.0
OP margin (%)	-238.2	-5.7	59.9	53.9
Net margin (%)	-217.6	10.6	52.6	58.2

**Balance sheet (summarized)**

(Wbn)	2023	2024F	2025F	2026F
<b>Current assets</b>	<b>135</b>	<b>640</b>	<b>800</b>	<b>964</b>
Cash & equivalents	63	214	400	602
AR & other receivables	18	24	15	18
Inventory	0	1	0	0
Other current assets	54	401	385	344
<b>Non-current assets</b>	<b>55</b>	<b>76</b>	<b>48</b>	<b>43</b>
Investments in associates	8	28	7	7
PP&E	25	24	21	19
Intangible assets	7	6	5	4
<b>Total assets</b>	<b>190</b>	<b>717</b>	<b>848</b>	<b>1,007</b>
<b>Current liabilities</b>	<b>37</b>	<b>72</b>	<b>39</b>	<b>36</b>
AP & other payables	12	15	15	13
Short-term financial liabilities	12	13	12	12
Other current liabilities	13	44	12	11
<b>Non-current liabilities</b>	<b>4</b>	<b>7</b>	<b>7</b>	<b>6</b>
Long-term financial liabilities	1	1	1	1
Other non-current liabilities	3	6	6	5
<b>Total liabilities</b>	<b>41</b>	<b>79</b>	<b>46</b>	<b>42</b>
<b>Equity attributable to owners</b>	<b>148</b>	<b>638</b>	<b>802</b>	<b>965</b>
Capital stock	14	18	18	18
Capital surplus	98	568	568	568
Retained earnings	31	42	206	369
<b>Minority interests</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Shareholders' equity</b>	<b>148</b>	<b>638</b>	<b>802</b>	<b>965</b>

**Cash flow statement (summarized)**

(Wbn)	2023	2024F	2025F	2026F
<b>Operating cash flow</b>	<b>-62</b>	<b>42</b>	<b>161</b>	<b>162</b>
NP	-74	13	164	163
Non-cash income/expenses	10	3	27	-9
Depreciation	3	3	3	3
Amortization	2	1	1	1
Other	5	-1	23	-13
Chg. in working capital	-2	14	-7	-5
Chg. in AR & other receivables	-7	1	0	1
Chg. in inventory	0	0	0	0
Chg. in AP & other payables	0	0	0	-1
Income tax	-1	-1	-48	-19
<b>Cash flow from investing activities</b>	<b>9</b>	<b>-349</b>	<b>6</b>	<b>40</b>
Chg. in PP&E	-1	-1	0	0
Chg. in intangible assets	-1	0	0	0
Chg. in financial assets	10	-337	6	40
Other	1	-11	0	0
<b>Cash flow from financing activities</b>	<b>-2</b>	<b>473</b>	<b>-1</b>	<b>0</b>
Chg. in financial liabilities	0	1	-1	0
Chg. in equity	4	475	0	0
Dividends	0	0	0	0
Other	-6	-3	0	0
<b>Chg. in cash</b>	<b>-55</b>	<b>151</b>	<b>186</b>	<b>202</b>
Beginning balance	118	63	214	400
Ending balance	63	214	400	602

Source: Company data, Mirae Asset Securities Research estimates

**Key valuation metrics/ratios**


	2023	2024F	2025F	2026F
P/E (x)	-	354.1	29.2	29.4
P/CF (x)	-	289.7	25.1	31.0
P/B (x)	12.1	7.5	5.9	4.9
EV/EBITDA (x)	-	-	21.1	25.0
EPS (W)	-2,634	370	4,482	4,463
CFPS (W)	-2,272	452	5,218	4,224
BPS (W)	5,387	17,581	22,063	26,525
DPS (W)	0	0	0	0
Dividend payout ratio (%)	0.0	0.0	0.0	0.0
Dividend yield (%)	0.0	0.0	0.0	0.0
Revenue growth (%)	2.2	260.6	153.7	-10.5
EBITDA growth (%)	RR	RR	TTP	-19.0
OP growth (%)	RR	RR	TTP	-19.1
EPS growth (%)	RR	TTP	1,111.6	-0.4
AR turnover (x)	2.5	9.1	25.4	24.1
Inventory turnover (x)	172.6	288.3	749.1	1,669.9
AP turnover (x)	2.3	2.2	2.3	2.5
ROA (%)	-33.3	2.8	21.0	17.6
ROE (%)	-40.1	3.3	22.8	18.5
ROIC (%)	-211.1	-22.1	631.0	544.7
Debt-to-equity ratio (%)	27.9	12.3	5.7	4.4
Current ratio (%)	363.1	892.6	2,064.2	2,683.3
Net debt-to-equity ratio (%)	-65.3	-90.9	-95.5	-96.2
Interest coverage ratio (x)	-153.0	-11.1	293.6	243.9

# Appendix 1

## Important disclosures and disclaimers

### Two-year rating and TP history

Company	Date	Rating	TP (W)
LigaChem Biosciences (141080)	10/25/24	Buy	170,000
	05/29/24	Buy	86,000



### Stock ratings

Buy	Expected 12-month performance: +20% or greater
Trading Buy	Expected 12-month performance: +10% to +20%
Hold	Expected 12-month performance: -10% to +10%
Sell	Expected 12-month performance: -10% or worse

### Sector ratings

Overweight	Expected to outperform the market over 12 months
Neutral	Expected to perform in line with the market over 12 months
Underweight	Expected to underperform the market over 12 months

Rating and TP history: Share price (—), TP (—), Not Rated (■), Buy (▲), Trading Buy (■), Hold (●), Sell (◆)

\* Our investment rating is a guide to the expected return of the stock over the next 12 months.

\* Outside of the official ratings of Mirae Asset Securities Co., Ltd., analysts may call trading opportunities should technical or short-term material developments arise.

\* The TP was determined by the research analyst through valuation methods discussed in this report, in part based on estimates of future earnings.

\* TP achievement may be impeded by risks related to the subject securities and companies, as well as general market and economic conditions.

### Ratings distribution and investment banking services

	Buy	Trading Buy	Hold	Sell
Ratings distribution	82.38%	10.23%	7.39%	0%
Investment banking services	84.21%	5.26%	10.53%	0%

\* Based on recommendations in the last 12-months (as of September 30, 2024)

### Disclosures

As of the publication date, Mirae Asset Securities Co., Ltd. is acting as a financial advisor to LigaChem Biosciences for its treasury share buyback and cancellation.

### Analyst certification

The research analysts who prepared this report (the "Analysts") are registered with the Korea Financial Investment Association and are subject to Korean securities regulations. They are neither registered as research analysts in any other jurisdiction nor subject to the laws or regulations thereof. Each Analyst responsible for the preparation of this report certifies that (i) all views expressed in this report accurately reflect the personal views of the Analyst about any and all of the issuers and securities named in this report and (ii) no part of the compensation of the Analyst was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report. Mirae Asset Securities Co., Ltd. ("Mirae Asset Securities") policy prohibits its Analysts and members of their households from owning securities of any company in the Analyst's area of coverage, and the Analysts do not serve as an officer, director, or advisory board member of the subject companies. Except as otherwise specified herein, the Analysts have not received any compensation or any other benefits from the subject companies in the past 12 months and have not been promised the same in connection with this report. Like all employees of Mirae Asset Securities, the Analysts receive compensation that is determined by overall firm profitability, which includes revenues from, among other business units, the institutional equities, investment banking, proprietary trading, and private client divisions. At the time of publication of this report, the Analysts do not know or have reason to know of any actual, material conflict of interest of the Analyst or Mirae Asset Securities except as otherwise stated herein.

### Disclaimers

This report was prepared by Mirae Asset Securities, a broker-dealer registered in the Republic of Korea and a member of the Korea Exchange. Information and opinions contained herein have been compiled in good faith and from sources believed to be reliable, but such information has not been independently verified and Mirae Asset Securities makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness, or correctness of the information and opinions contained herein or of any translation into English from the Korean language. In case of an English translation of a report prepared in the Korean language, the original Korean language report may have been made available to investors in advance of this report.

The intended recipients of this report are sophisticated institutional investors who have substantial knowledge of the local business environment, its common practices, laws, and accounting principles, and no person whose receipt or use of this report would violate any laws or regulations or subject Mirae Asset Securities or any of its affiliates to registration or licensing requirements in any jurisdiction shall receive or make any use hereof.

This report is for general information purposes only and is not and shall not be construed as an offer or a solicitation of an offer to effect transactions in any securities or other financial instruments. The report does not constitute investment advice to any person, and such person shall not be treated as a client of Mirae Asset Securities by virtue of receiving this report. This report does not take into account the particular investment objectives, financial situations, or needs of individual clients. The report is not to be relied upon in substitution for the exercise of independent judgment. Information and opinions contained herein are as of the date hereof and are subject to change without notice. The price and value of the investments referred to in this report and the income from them may depreciate or appreciate, and investors may incur losses on investments. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. Mirae Asset Securities, its affiliates, and their directors, officers, employees, and agents do not accept any liability for any loss arising out of the use hereof.

Mirae Asset Securities may have issued other reports that are inconsistent with, and reach different conclusions from, the opinions presented in this report.

The reports may reflect different assumptions, views, and analytical methods of the analysts who prepared them. Mirae Asset Securities may make investment decisions that are inconsistent with the opinions and views expressed in this research report. Mirae Asset Securities, its affiliates, and their directors, officers, employees, and agents may have long or short positions in any of the subject securities at any time and may make a purchase or sale, or offer to make a purchase or sale, of any such securities or other financial instruments from time to time in the open market or otherwise, in each case either as principals or agents. Mirae Asset Securities and its affiliates may have had, or may be expecting to enter into, business relationships with the subject companies to provide investment banking, market-making, or other financial services as are permitted under applicable laws and regulations.

No part of this document may be copied or reproduced in any manner or form or redistributed or published, in whole or in part, without the prior written consent of Mirae Asset Securities. For further information regarding company-specific information as it pertains to the representations and disclosures in this Appendix 1, please contact [compliance@miraeasset.us.com](mailto:compliance@miraeasset.us.com) or +1 (212) 407-1000.

#### **Distribution**

**United Kingdom:** This report is being distributed by Mirae Asset Securities (UK) Ltd. in the United Kingdom only to (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (ii) high net worth companies and other persons to whom it may lawfully be communicated, falling within Article 49(2)(A) to (E) of the Order (all such persons together being referred to as "Relevant Persons"). This report is directed only at Relevant Persons. Any person who is not a Relevant Person should not act or rely on this report or any of its contents.

**United States:** Mirae Asset Securities is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This report is distributed in the U.S. by Mirae Asset Securities (USA) Inc., a member of FINRA/SIPC, to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6(b)(4) under the U.S. Securities Exchange Act of 1934, as amended. All U.S. persons that receive this document by their acceptance hereof represent and warrant that they are a major U.S. institutional investor and have not received this report under any express or implied understanding that they will direct commission income to Mirae Asset Securities or its affiliates. Any U.S. recipient of this document wishing to effect a transaction in any securities discussed herein should contact and place orders with Mirae Asset Securities (USA) Inc. Mirae Asset Securities (USA) Inc. accepts responsibility for the contents of this report in the U.S., subject to the terms hereof, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Mirae Asset Securities. The securities described in this report may not have been registered under the U.S. Securities Act of 1933, as amended, and, in such case, may not be offered or sold in the U.S. or to U.S. persons absent registration or an applicable exemption from the registration requirements.

**Hong Kong:** This report is distributed in Hong Kong by Mirae Asset Securities (HK) Limited, which is regulated by the Hong Kong Securities and Futures Commission. The contents of this report have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule 1 to the Securities and Futures Ordinance of Hong Kong (Cap. 571, Laws of Hong Kong) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person.

**India:** This report is being distributed by Mirae Asset Capital Markets (India) Private Limited ("MACM") in India to the customers based in India and is personal information only for those authorised recipient(s). MACM is inter alia a Securities and Exchange Board of India ("SEBI") registered Research Analyst in India and is not registered outside India. MACM and Mirae Asset, Korea are group entities. MACM makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information and opinions contained herein. The user assumes the entire risk of any use made of this information. This report has been provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipient must read the entire Appendix 1 to the report carefully for Important Disclosures & Disclaimers.

**All other jurisdictions:** Customers in all other countries who wish to effect a transaction in any securities referenced in this report should contact Mirae Asset Securities or its affiliates only if distribution to or use by such customer of this report would not violate applicable laws and regulations and not subject Mirae Asset Securities and its affiliates to any registration or licensing requirement within such jurisdiction.

**Mirae Asset Securities International Network**

**Mirae Asset Securities Co., Ltd. (Seoul)**

One-Asia Equity Sales Team  
Mirae Asset Center 1 Building  
26 Eulji-ro 5-gil, Jung-gu, Seoul 04539  
Korea

Tel: 82-2-3774-2124

**Mirae Asset Securities (USA) Inc.**

810 Seventh Avenue, 37th Floor  
New York, NY 10019  
USA

Tel: 1-212-407-1000

**Mirae Asset Securities (Singapore) Pte. Ltd.**

6 Battery Road, #11-01  
Singapore 049909  
Republic of Singapore

Tel: 65-6671-9845

**Mirae Asset Investment Advisory (Beijing) Co., Ltd**

2401B, 24th Floor, East Tower, Twin Towers  
B12 Jianguomenwai Avenue, Chaoyang District  
Beijing 100022  
China

Tel: 86-10-6567-9699

**Ho Chi Minh Representative Office**

7F, Saigon Royal Building  
91 Pasteur St.  
District 1, Ben Nghe Ward, Ho Chi Minh City  
Vietnam

Tel: 84-8-3910-7715

**Mirae Asset Securities (HK) Ltd.**

Units 8501, 8507-8508, 85/F  
International Commerce Centre  
1 Austin Road West  
Kowloon  
Hong Kong  
Tel: 852-2845-6332

**Mirae Asset Wealth Management (Brazil) CCTVM**

Rua Funchal, 418, 18th Floor, E-Tower Building  
Vila Olimpia  
Sao Paulo - SP  
04551-060  
Brazil  
Tel: 55-11-2789-2100

**Mirae Asset Securities (Vietnam) LLC**

7F, Saigon Royal Building  
91 Pasteur St.  
District 1, Ben Nghe Ward, Ho Chi Minh City  
Vietnam

Tel: 84-8-3911-0633 (ext.110)

**Beijing Representative Office**

2401A, 24th Floor, East Tower, Twin Towers  
B12 Jianguomenwai Avenue, Chaoyang District  
Beijing 100022  
China

Tel: 86-10-6567-9699 (ext. 3300)

**Mirae Asset Capital Markets (India) Pvt Ltd**

1st Floor, Tower 4, Equinox Business Park,  
LBS Marg, Off BKC, Kurla (West), Mumbai - 400 070  
India

Tel: 91-22-62661300 / 48821300

**Mirae Asset Securities (UK) Ltd.**

41st Floor, Tower 42  
25 Old Broad Street,  
London EC2N 1HQ  
United Kingdom

Tel: 44-20-7982-8000

**PT. Mirae Asset Sekuritas Indonesia**

District 8, Treasury Tower Building Lt. 50  
Sudirman Central Business District  
Jl. Jend. Sudirman, Kav. 52-54  
Jakarta Selatan 12190  
Indonesia  
Tel: 62-21-5088-7000

**Mirae Asset Securities Mongolia UTsk LLC**

#406, Blue Sky Tower, Peace Avenue 17  
1 Khoroo, Sukhbaatar District  
Ulaanbaatar 14240  
Mongolia

Tel: 976-7011-0806

**Shanghai Representative Office**

38T31, 38F, Shanghai World Financial Center  
100 Century Avenue, Pudong New Area  
Shanghai 200120  
China

Tel: 86-21-5013-6392